ATS View
한국어

GemVax & KAEL KRX:082270KOSDAQ

젬백스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked16since Sep 11

In Q2 2026, GemVax & KAEL reported revenue of ₩22.7bn, down 9.2% year on year, and operating profit of ₩997m. GemVax & KAEL (젬백스) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 22 with 1 article.

Filing signals Turnaround Major holder adding Control change Treasury share sale Screener

GemVax & KAEL quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩22.7bn-9.2%₩997m
margin 4.4%		−₩9.9bn
Q1 2026₩18.3bn+47.6%−₩765m
margin −4.2%		−₩1.5bn
Q4 2025 derived₩26.2bn+43.2%₩7.5bn
margin 28.7%		₩1.6bn
Q3 2025₩18.0bn+41.2%₩723m
margin 4.0%		−₩2.5bn
Q2 2025₩25.0bn+47.6%−₩1.5bn
margin −6.0%		−₩1.6bn
Q1 2025₩12.4bn-16.0%−₩3.0bn
margin −23.9%		−₩8.9bn
Q4 2024 derived₩18.3bn-0.2%−₩8.2bn
margin −44.7%		−₩46.7bn
Q3 2024₩12.7bn-6.2%−₩8.9bn
margin −69.6%		−₩8.2bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

GemVax & KAEL top stories 2 weeks, by number of outlets

  1. 1
    젬백스 최대주주 대출 9000만원 상환…담보계약 2027년 4월까지
    1 outlets · 1 articlesFirst report Oct 22 06:55 비건뉴스

Latest GemVax & KAEL news Korean headlines